BCR and chronic myelogenous leukemia, BCR-ABL1 positive: It has shown promising effects against CML, especially by targeting the BCR-ABL oncoprotein and several studies have explored how emodin works in CML cells, including those that are resistant to commonly used TKIs like imatinib.